Covid-19 manufacturing roundup: EMA clears 2 New England manufacturing sites for Covid-19 vaccine scale up; Incentives, tax breaks highlight South Korea's efforts to be vaccine powerhouse
The EMA has approved a scale-up of production of Moderna’s Covid-19 vaccine Spikevax at two New England sites.
If all goes according to plan, the US supply chain will provide 40 million doses of the vaccine to the EU in Q3 of 2021.
Moderna’s Norwood, MA site and Lonza’s Portsmouth, NH site nearly 81 miles away will both increase their production capacity, the EMA said in a press release Tuesday. Since granting emergency use authorization for Moderna’s jab, the EMA’s human medicines committee has authorized four sites for the production of drug substances: two in the US and two in Visp, Switzerland.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
